Regeneron Pharmaceuticals (REGN) Receivables - Other (2009 - 2020)

Regeneron Pharmaceuticals' Receivables - Other history runs 12 years deep, the most recent figure standing at $460.8 million for Q3 2020.

• On a quarterly basis, Receivables - Other rose 33.41% year-over-year to $460.8 million in Q3 2020; TTM through Sep 2020 was $460.8 million, a 33.41% increase from a year earlier, with the FY2019 full-year figure at $260.6 million, up 15.11% from the prior year.
• Receivables - Other rose to $460.8 million in Q3 2020 per REGN's latest filing, from $389.2 million in the prior quarter.
• Across five years, Receivables - Other topped out at $468.3 million in Q1 2020 and bottomed at $93.0 million in Q4 2016.
• The 5-year median for Receivables - Other is $226.4 million (2018), against an average of $249.8 million.
• Across the five-year window, Receivables - Other sank 39.28% in 2016 and jumped 108.3% in 2017, its largest moves.
• Year by year, Receivables - Other stood at $93.0 million in 2016, then soared by 108.3% to $193.7 million in 2017, then climbed by 16.88% to $226.4 million in 2018, then climbed by 15.11% to $260.6 million in 2019, then surged by 76.82% to $460.8 million in 2020.
• Per Business Quant, the three latest REGN Receivables - Other figures stand at $460.8 million (Q3 2020), $389.2 million (Q2 2020), and $468.3 million (Q1 2020).